Last reviewed · How we verify
Psychiatric Drugs
At a glance
| Generic name | Psychiatric Drugs |
|---|---|
| Also known as | Antipsychotics, Benzodiazepines, antidepressants, mood stabilizers |
| Sponsor | Mark Weiser, MD, Principal Investigator |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People (EARLY_PHASE1)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community (NA)
- Gender Differences in Depression Severity, Gender-Sensitive Symptoms, Resilience, and Stigma in Major Depressive Disorder
- Seeking Treatment for Gambling - a 10-year Retrospective Clinical and Register Study of Gambling Patterns and Physical and Psychiatric Comorbidity in Patients With Gambling Disorder
- Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD (NA)
- Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers
- Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Psychiatric Drugs CI brief — competitive landscape report
- Psychiatric Drugs updates RSS · CI watch RSS
- Mark Weiser, MD, Principal Investigator portfolio CI